Your Journey. Your Story. Your Strength.
Integrated Cancer Ranking Table (Based on 2025 Data)
by: OcularCancer.com
July 30, 2025
1 Minute Read
This table provides a side-by-side comparison of 25 major cancer types ranked by prevalence, aggressiveness, and curability based on the latest available data for 2025.
Prevalence Rank indicates how common the cancer is in the U.S. based on annual new case estimates.
Aggressiveness Rank reflects how quickly the cancer typically progresses and its potential to metastasize or cause death.
Curability Rank considers the general likelihood of long-term survival or remission based on current treatments.
This table is meant as an educational overview - not a substitute for medical advice.
📊 Integrated Cancer Ranking Table (Based on 2025 Data)
This table provides a side-by-side comparison of 25 major cancer types ranked by prevalence, aggressiveness, and curability based on the latest available data for 2025. It is designed to help patients, advocates, clinicians, and researchers quickly grasp the relative burden and clinical challenges associated with each type of cancer.
Prevalence Rank indicates how common the cancer is in the U.S. based on annual new case estimates.
Aggressiveness Rank reflects how quickly the cancer typically progresses and its potential to metastasize or cause death.
Curability Rank considers the general likelihood of long-term survival or remission based on current treatments.
While rankings offer valuable insight, every cancer case is unique. Diagnosis, treatment response, and prognosis vary widely depending on subtype, stage, genetics, and individual health factors. This table is meant as an educational overview - not a substitute for medical advice.
Cancer Type | Prevalence | Aggressiveness | Curability |
Breast Cancer | 1 | 19 (varies by subtype) | 16 |
Prostate Cancer | 2 | 16 (high-grade types) | 15 |
Lung & Bronchus (NSCLC/SCLC) | 3 | 3 (SCLC), 13 (NSCLC) | 9-14 |
Colorectal Cancer | 4 | 14 | 12 |
Melanoma (Skin) | 5 | 12 (metastatic) | 8 |
Bladder Cancer | 6 | 15 (variable) | ~10-13* |
Non-Hodgkin Lymphoma (NHL) | 7 | Variable by subtype | Variable |
Kidney (Renal Cell) Cancer | 8 | 15 | ~13-15* |
Endometrial (Uterine) Cancer | 9 | ~18-19 | 17 |
Leukemia (All Types) | 10 | 10 (AML), 20 (CLL) | 11, 22 |
Pancreatic Cancer | 11 | 1 | 1 |
Thyroid Cancer | 12 | 21 | 18 |
Oral & Oropharyngeal Cancer | 13 | ~13-16 | ~10-14* |
Liver & Bile Duct Cancer | 14 | 8 | 6 |
Stomach (Gastric) Cancer | 15 | ~13-15 | ~10-13* |
Brain & CNS (includes Glioblastoma) | 16 | 2 | 2 |
Esophageal Cancer | 17 | 5 | 5 |
Ovarian Cancer | 18 | 6 | 10 |
Gallbladder/Bile Duct | 19 | 4 | 4 |
Small Intestine Cancer | 20 | ~15-17 | ~13-16* |
Testicular Cancer | 21 | 18 | 20 |
Hodgkin Lymphoma | 22 | 17 | 19 |
Ocular Melanoma (Uveal) | 23 | 7 | 7 |
Mesothelioma | 24 | 11 | 3 |
Appendiceal Cancer | 25 | ~14-16 (limited data) | ~10-15* |
🧠 Notes & Assumptions:
“~” means variable or estimated based on similar cancers or subtype data.
Subtypes of some cancers (e.g., breast, leukemia, melanoma) vary widely in aggressiveness and curability.
Rankings 1-25 for aggressiveness and curability are standardized to match the prevalence list only.
Cancers without firm placement in original lists are estimated from clinical data and literature.